HealthEquity, Inc. terminated Michael Fiore as Chief Commercial Officer without cause, effective October 5, 2026, and will redistribute his responsibilities among other members of its management team.
HQY · Healthequity, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
HealthEquity appointed Noémie Heuland, Moody’s Corporation’s CFO, to its board effective September 24, 2026, expanding it to eleven members; she will join the Audit and Risk and Cybersecurity and Technology Committees.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY27 earnings call · Aug 27, 2026TL;DR. Q2 delivered higher revenue, net income, and adjusted EBITDA, a record adjusted EBITDA margin, strong HSA growth, and raised fiscal 2027 guidance. Operational efficiencies reduced calls, while the company generated operating cash flow and repurchased stock; risks include CDB product shifts, service-price erosion, a $3.3 million disposal expense, immaterial Marketplace revenue, competition, and cybersecurity exposure.
- + Q2 revenue increased 8%, net income increased 10%, adjusted EBITDA increased 11%, and adjusted EBITDA margin rose to 48% from 46%.
- + Management raised fiscal 2027 revenue guidance to $1.411 billion-$1.421 billion and adjusted EBITDA guidance to $628 million-$636 million.
- + Total HSA assets increased 14% year over year to $37.9 billion.
- + HSAs increased 8% year over year to 10.7 million, while HSAs with investments increased 20% to 0.9 million.
- + Operational efficiencies reduced human-handled calls 25% year over year and card-related calls 30%.
- + The company generated $136 million of operating cash flow and repurchased approximately $108 million of stock during the quarter.
- − Some clients are shifting from other CDB products, particularly FSA, toward greater HSA adoption.
- − Headline price erosion is a headwind to year-over-year service revenue growth.
- − Q2 results included a $3.3 million one-time disposal expense for unused internally developed software.
- − Marketplace revenue remains immaterial to overall financial results.
- − HealthEquity faces significant competition, including competitors with greater resources.
- − Potential cybersecurity breaches could cause costs, liabilities, reputational damage, and loss of business.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $167M | second quarter ended July 31, 2026 | — |
|
|
|||
| Adjusted EBITDA margin non-GAAP | 48% | second quarter ended July 31, 2026 | +0.0% |
|
|
|||
| Average daily Client-held funds - Quarter-to-date | 936M | July 31, 2026 | — |
| Average daily Client-held funds - Year-to-date | 986M | July 31, 2026 | — |
| Average daily HSA cash - Quarter-to-date | 17.39B | July 31, 2026 | — |
| Average daily HSA cash - Year-to-date | 17.55B | July 31, 2026 | — |
| Average Total Accounts - Quarter-to-date | 17.71M | July 31, 2026 | — |
| Average Total Accounts - Year-to-date | 17.77M | July 31, 2026 | — |
| CDBs | 7.02M | July 31, 2026 | — |
| Client-held funds | $0.9B | as of July 31, 2026 | — |
| HSA cash | $17.4B | as of July 31, 2026 | — |
| HSA investments | $20.6B | as of July 31, 2026 | — |
| HSAs | 10.7M | as of July 31, 2026 | — |
| HSAs with investments | 0.9M | as of July 31, 2026 | — |
| New HSAs from sales | 202K | second quarter ended July 31, 2026 | — |
| New HSAs from sales - Quarter-to-date | 202K | July 31, 2026 | — |
| New HSAs from sales - Year-to-date | 374K | July 31, 2026 | — |
| Non-GAAP net income non-GAAP | $103.8M | second quarter ended July 31, 2026 | — |
|
|
|||
| Non-GAAP net income per diluted share non-GAAP | $1.24 | second quarter ended July 31, 2026 | +0.0% |
|
|
|||
| Remaining stock repurchase authorization | $948.4M | as of July 31, 2026 | — |
| Shares repurchased | 1.2M | second quarter ended July 31, 2026 | — |
| Stock repurchases | $108.1M | second quarter ended July 31, 2026 | — |
| Total Accounts | 17.8M | as of July 31, 2026 | — |
| Total HSA Assets | $37.9B | as of July 31, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Health Information Services — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HQY
this stock
Healthequity, Inc.
|
$8.56B | +12.9% | +28.7% | 37.4 | 6.6% |
|
VEEV
Veeva Systems Inc
|
$48.82B | +35.1% | +28.1% | 49.4 | 2.4% |
|
PMDIY
Pro Medicus Ltd.
|
$14.81B | -14.6% | — | — | 0.0% |
|
BTSG
BrightSpring Health Services, Inc.
|
$14.17B | +90.1% | +28.2% | 38.7 | 5.8% |
|
TEM
Tempus AI, Inc.
|
$13.06B | +21.3% | +83.4% | — | 13.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 9, 2026
- This year
- 17
HealthEquity, Inc. terminated Michael Fiore as Chief Commercial Officer without cause, effective October 5, 2026, and will redistribute his responsibilities among other members of its management team.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HQY | -0.2% | +12.4% | +18.6% | +1.0% | +12.9% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.8% | +13.6% | +18.1% | +1.2% | +2.3% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.